Analysts have given Gilead Sciences a total of 15 ratings, with the consensus rating being Outperform. The average one-year ...

Stock Market LIVE Updates | India's benchmark indexes opened higher on Wednesday, driven by optimism over easing trade ...

Capital Group Private Client Services Inc. reduced its Regeneron holdings by 17.6% in Q4, offloading 19,565 shares, but still ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

F M Investments boosted its stake in Regeneron Pharmaceuticals by 8.5% in Q4, grabbing 7,003 shares worth nearly $5 million.

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

Biocon Biologics Ltd, announced today a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili™ (aflibercept-jbvf), an interchangeable* biosimilar aflibercept, ...

As per provisional closing, the barometer index, the S&P BSE Sensex, surged 1,577.63 points or 2.16% to 76,734.89. The Nifty 50 index rallied 500 points or 2.19% to 23,328.55.

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

PARIS, France I April 15, 2025 I Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for ...

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPDNew phase 2 data for amlitelimab show ...